They either see themselves in the condition or they don't
be wary of any company claiming to have compounded GLP-1 drugs that are FDA-approved
[13] [14] UK SmPCs for licensed GLP-1 receptor agonists do not list medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) as formal contraindications, but advise vigilance for symptoms such as a neck lump, hoarseness, or difficulty swallowing
Regulatory Considerations: Reusable autoinjectors face higher regulatory scrutiny
Some drugs have been proposed to accelerate -cell loss (e.g., glibenclamide and glyburide) [23], while other drugs such as peroxisome proliferator-activated receptor-gamma (PPAR) agonists, GLP-1 receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, glycogen synthase kinase 3 (GSK3) inhibitors, or G protein-coupled receptor 40 (GPR40) agonists have been suggested to protect -cell function [16]